concomitant temozolomide (TMZ)

Phase 3Small molecule

AAlliance for Clinical Trials in Oncology

concomitant temozolomide (TMZ) is one of 19 small molecule programs targeting Low Grade Glioma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Low Grade GliomaActive, not recruiting

Low Grade GliomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

19 competitors in Low Grade Glioma

#DrugCompanyPhaseTrials

Tafinlar

Novartis

Approved

2 2

Plaquenil

Jazz Pharmaceuticals

Approved

1 3

Mektovi

Pfizer

Approved

—4

Rapamune

PPrism Pharmaceuticals

Approved

—5

Tasigna

AAzurity Pharmaceuticals

Approved

—6

Navelbine

PPierre Fabre Medicament

Approved

—7

Caprelsa

GGenzyme, a Sanofi Company

Koselugo

2 9

Oncovin

Eli Lilly

Phase 3

1 10

Avastin

Roche

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 3Active, not recruiting

Low Grade Glioma

NCT00887146

Clinical

Trials by Indication[1]

Low Grade Glioma1 trial

Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma

Active, not recruiting·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00887146·305 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for concomitant temozolomide (TMZ). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — concomitant temozolomide (TMZ) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for concomitant temozolomide (TMZ). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Alliance for Clinical Trials in Oncology company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAlliance for Clinical Trials in Oncology

concomitant temozolomide (TMZ)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Low Grade Glioma1 trial

References

Drug Info

Quick Facts

Related News